126 related articles for article (PubMed ID: 6863976)
1. Inhibition of a Langerhans cell-mediated immune response by treatment modalities useful in psoriasis.
Morhenn VB; Orenberg EK; Kaplan J; Pfendt E; Terrell C; Engleman EG
J Invest Dermatol; 1983 Jul; 81(1):23-7. PubMed ID: 6863976
[TBL] [Abstract][Full Text] [Related]
2. An investigation of the ability of antipsoriatic drugs to inhibit calmodulin activity: a possible mode of action of dithranol (anthralin).
Tucker WF; MacNeil S; Dawson RA; Tomlinson S; Bleehen SS
J Invest Dermatol; 1986 Aug; 87(2):232-5. PubMed ID: 3016102
[TBL] [Abstract][Full Text] [Related]
3. Immunologic mechanisms in psoriasis.
Gottlieb AB
J Am Acad Dermatol; 1988 Jun; 18(6):1376-80. PubMed ID: 3290292
[TBL] [Abstract][Full Text] [Related]
4. Comparison of antiproliferative effects of experimental and established antipsoriatic drugs on human keratinocytes, using a simple 96-well-plate assay.
Pol A; Bergers M; Schalkwijk J
In Vitro Cell Dev Biol Anim; 2003; 39(1-2):36-42. PubMed ID: 12892525
[TBL] [Abstract][Full Text] [Related]
5. The autologous mixed epidermal cell-T lymphocyte reaction is elevated in psoriasis: a crucial role for epidermal HLA-DR+/CD1a- antigen-presenting cells.
Prens EP; Benne K; van Joost T; Benner R
J Invest Dermatol; 1991 Jun; 96(6):880-7. PubMed ID: 1710638
[TBL] [Abstract][Full Text] [Related]
6. Effects of topical corticosteroid therapy on Langerhans cell antigen presenting function in human skin.
Ashworth J; Booker J; Breathnach SM
Br J Dermatol; 1988 Apr; 118(4):457-69. PubMed ID: 3288268
[TBL] [Abstract][Full Text] [Related]
7. Langerhans' cells in patients with psoriasis: effect of treatment with PUVA, PUVA bath, etretinate and anthralin.
Czernielewski J; Juhlin L; Shroot S; Brun P
Acta Derm Venereol; 1985; 65(2):97-101. PubMed ID: 2408430
[TBL] [Abstract][Full Text] [Related]
8. T-lymphocyte-activating properties of epidermal antigen-presenting cells from normal and psoriatic skin: evidence that psoriatic epidermal antigen-presenting cells resemble cultured normal Langerhans cells.
Demidem A; Taylor JR; Grammer SF; Streilein JW
J Invest Dermatol; 1991 Sep; 97(3):454-60. PubMed ID: 1875046
[TBL] [Abstract][Full Text] [Related]
9. The antipsoriatic drug, anthralin, inhibits protein kinase C--implications for its mechanism of action.
Hegemann L; Fruchtmann R; van Rooijen LA; Müller-Peddinghaus R; Mahrle G
Arch Dermatol Res; 1992; 284(3):179-83. PubMed ID: 1503504
[TBL] [Abstract][Full Text] [Related]
10. Density of epidermal Langerhans cells in psoriasis patients treated with an aromatic retinoid (RO 10-9359). An immunoperoxidase study using anti-T6 and anti-Ia monoclonal antibodies.
Guzman de Fleury M; Tapia FJ; Soto J; Ghersi N; Convit J
Histol Histopathol; 1986 Jul; 1(3):227-34. PubMed ID: 2856536
[TBL] [Abstract][Full Text] [Related]
11. [Effect of topical antipsoriatic agents on ATPase-positive epidermal Langerhans cells. Animal experiment studies].
Gruner S; Strunk D; Diezel W
Dermatol Monatsschr; 1987; 173(8):436-40. PubMed ID: 2959574
[No Abstract] [Full Text] [Related]
12. A simple technique for high-throughput screening of drugs that modulate normal and psoriasis-like differentiation in cultured human keratinocytes.
Pol A; Bergers M; van Ruissen F; Pfundt R; Schalkwijk J
Skin Pharmacol Appl Skin Physiol; 2002; 15(4):252-61. PubMed ID: 12218287
[TBL] [Abstract][Full Text] [Related]
13. The interleukin-8 receptor: a potential target for antipsoriatic therapy?
Kemény L; Kenderessy AS; Olasz E; Michel G; Ruzicka T; Farkas B; Dobozy A
Eur J Pharmacol; 1994 Jun; 258(3):269-72. PubMed ID: 8088360
[TBL] [Abstract][Full Text] [Related]
14. Anthralin derivatives--inhibition of 5-lipoxygenase--antipsoriatic efficacy.
Tanzer H; Braun C; Seidel M; Wiegrebe W
Arch Pharm (Weinheim); 1991 Nov; 324(11):841-6. PubMed ID: 1804060
[TBL] [Abstract][Full Text] [Related]
15. Magnesium ions inhibit the antigen-presenting function of human epidermal Langerhans cells in vivo and in vitro. Involvement of ATPase, HLA-DR, B7 molecules, and cytokines.
Schempp CM; Dittmar HC; Hummler D; Simon-Haarhaus B; Schulte-Mönting J; Schöpf E; Simon JC
J Invest Dermatol; 2000 Oct; 115(4):680-6. PubMed ID: 10998143
[TBL] [Abstract][Full Text] [Related]
16. Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals.
Müller K
Biochem Pharmacol; 1997 May; 53(9):1215-21. PubMed ID: 9214681
[TBL] [Abstract][Full Text] [Related]
17. Mixed epidermal cell lymphocyte reaction: HLA-DR+ cells exhibit a greater immunostimulatory activity than CD1a+ cells.
Dobmeyer TS; Dobmeyer JM; Klein SA; Schopf RE; Helm EB; Rossol R
Adv Exp Med Biol; 1995; 378():393-6. PubMed ID: 8526102
[No Abstract] [Full Text] [Related]
18. Langerhans cells in skin from patients with psoriasis: quantitative and qualitative study of T6 and HLA-DR antigen-expressing cells and changes with aromatic retinoid administration.
Haftek M; Faure M; Schmitt D; Thivolet J
J Invest Dermatol; 1983 Jul; 81(1):10-4. PubMed ID: 6345681
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis.
Cooper KD; Baadsgaard O; Ellis CN; Duell E; Voorhees JJ
J Invest Dermatol; 1990 May; 94(5):649-56. PubMed ID: 2324521
[TBL] [Abstract][Full Text] [Related]
20. Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques.
Gottlieb AB; Lifshitz B; Fu SM; Staiano-Coico L; Wang CY; Carter DM
J Exp Med; 1986 Oct; 164(4):1013-28. PubMed ID: 2428913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
